Mounjaro and Zepbound side effects by dose: the rates at each step
Reviewed 7 sourcesPublished by PepVault
Mounjaro and Zepbound side effects at 5, 10 and 15 mg against placebo, from the labels' trial tables: when they show up, how many stopped, and what helps.

- Last reviewed
- Sources
- 7
- Questions
- 9
- Compounds
- 2
The short answer
In Zepbound's weight trials, nausea affected 25%, 29% and 28% of people on 5, 10 and 15 mg, against 8% on placebo; diarrhoea, vomiting and constipation came next. Mounjaro's diabetes trials saw lower rates. Most stomach effects came during the dose climb and eased over time, and 4.8% to 6.7% stopped for any side effect, against 3.4% on placebo. Smaller meals, stopping at fullness and steady fluids help.
Evidence: FDA prescribing information for Zepbound and Mounjaro, whose adverse-reaction tables pool randomised placebo-controlled phase 3 trials in people, plus the SURMOUNT-1, SURPASS-1 and SURPASS-2 papers and two Lilly-funded post hoc analyses.

What are the side effects of Zepbound at each dose?
Stomach effects lead at every dose. Mounjaro and Zepbound are the same medicine, tirzepatide, sold under two names: Zepbound for weight loss and Mounjaro for type 2 diabetes. Tirzepatide acts on two gut-hormone receptors, GIP and GLP-1, and it slows how fast the stomach empties1. Food sits longer, which goes with the fullness and the nausea.
The Zepbound label pools two weight trials of up to 72 weeks, SURMOUNT-1 in adults without diabetes and a second in adults with type 2 diabetes, 2,519 people on tirzepatide in all. The second trial had no 5 mg group, so the 5 mg column comes from SURMOUNT-1 alone. The label lists every effect seen in at least 2% and more often than on placebo; these are the most common, as the share of each group, as of the August 2026 label1:
| Effect | 5 mg | 10 mg | 15 mg | Placebo |
|---|---|---|---|---|
| Nausea | 25% | 29% | 28% | 8% |
| Diarrhoea | 19% | 21% | 23% | 8% |
| Vomiting | 8% | 11% | 13% | 2% |
| Constipation | 17% | 14% | 11% | 5% |
| Stomach pain | 9% | 9% | 10% | 5% |
| Indigestion (dyspepsia) | 9% | 9% | 10% | 4% |
| Injection site reactions | 6% | 8% | 8% | 2% |
| Tiredness | 5% | 6% | 7% | 3% |
| Allergic-type reactions, mostly rash or itching | 5% | 5% | 5% | 3% |
| Burping | 4% | 5% | 5% | 1% |
| Hair loss | 5% | 4% | 5% | 1% |
| Reflux | 4% | 4% | 5% | 2% |
| Dizziness | 4% | 5% | 4% | 2% |

Placebo groups report nausea and diarrhoea too, from ordinary life over 72 weeks. The gap between a dose and placebo is the part the medicine adds. Constipation is the one effect that fell as the dose rose.
Taken together, 56% of people on each dose had at least one stomach side effect, against 30% on placebo1. Most were mild to moderate: severe stomach effects were reported by 1.7%, 2.5% and 3.1% on 5, 10 and 15 mg, against 1% on placebo1.

Are Mounjaro side effects different from Zepbound's?
The same effects, at lower rates. The Mounjaro label pools two placebo-controlled diabetes trials, SURPASS-1 (tirzepatide alone) and SURPASS-5 (added to basal insulin), with 718 people on tirzepatide for an average of 37 weeks2:
| Effect | 5 mg | 10 mg | 15 mg | Placebo |
|---|---|---|---|---|
| Nausea | 12% | 15% | 18% | 4% |
| Diarrhoea | 12% | 13% | 17% | 9% |
| Less appetite | 5% | 10% | 11% | 1% |
| Vomiting | 5% | 5% | 9% | 2% |
| Constipation | 6% | 6% | 7% | 1% |
| Indigestion (dyspepsia) | 8% | 8% | 5% | 3% |
| Stomach pain | 6% | 5% | 5% | 4% |
Here the rates climb more clearly with the dose: any stomach side effect affected 37.1%, 39.6% and 43.6%, against 20.4% on placebo2. The two tables come from different people, trial lengths and designs, and the labels warn that rates from separate trials cannot be compared directly12. Against another GLP-1 the gap is small: in SURPASS-2, an open-label 40-week trial, nausea affected 17% to 22% on tirzepatide and 18% on semaglutide 1 mg7. SURPASS-1 on its own saw nausea in 12% to 18% over 40 weeks, against 6% on placebo6.
When do tirzepatide side effects start, and when do they fade?
Mostly in the climb. Both labels say most nausea, vomiting and diarrhoea came during dose escalation, the weeks when the dose is stepped up, and decreased over time12. The label climb starts at 2.5 mg for four weeks and adds 2.5 mg after at least four weeks on each dose, so the first 15 mg dose comes after 20 weeks at the earliest; SURMOUNT-1 used that 20-week climb13.

The pattern has a cause in the label. The slowing of the stomach is largest after the first dose and shrinks with the doses that follow1. A Lilly analysis of the four SURMOUNT trials found that when people needed medicine for nausea or diarrhoea, they most often first reached for it in the first 24 weeks, the stretch that held the climb4.
No primary source we found gives how many days after each step the effects peak, so this guide gives no day count. What each week tends to feel like is in PepVault's guide to tirzepatide week by week.
How many people stopped tirzepatide because of side effects?
Few, and most of those left early. Most people who stopped Zepbound for a side effect did so in the first few months, over stomach effects1.
| Stopped because of | 5 mg | 10 mg | 15 mg | Placebo |
|---|---|---|---|---|
| Any side effect, Zepbound weight trials | 4.8% | 6.3% | 6.7% | 3.4% |
| Any side effect, SURMOUNT-1 alone | 4.3% | 7.1% | 6.2% | 2.6% |
| Stomach side effects, Zepbound weight trials | 1.9% | 3.3% | 4.3% | 0.5% |
| Stomach side effects, Mounjaro diabetes trials | 3.0% | 5.4% | 6.6% | 0.4% |

The first three rows are from the Zepbound label and the SURMOUNT-1 paper13, the last from the Mounjaro label2. Across the four SURMOUNT trials, between 1.0% and 10.5% of people on tirzepatide stopped because of stomach effects4.
Does feeling sick mean tirzepatide is working?
Not in the trials. Across SURMOUNT-1 to -4, among people who stayed on treatment, weight loss was similar in those who reported no nausea, nausea alone, or any nausea, vomiting or diarrhoea; in SURMOUNT-1 to -3, those effects and indigestion together accounted for at most 3.1% of the total weight lost4. In the SURPASS diabetes trials, people who reported nausea, vomiting or diarrhoea lost 6.2 to 14.9 kg on average and those who did not lost 6.2 to 13.3 kg, and the stomach effects explained under 6% of tirzepatide's lead over placebo, semaglutide and insulin5. Both are Lilly-funded analyses made after the trials. A quiet stomach is not a sign the dose is doing less.
What helps with nausea and stomach upset on Mounjaro or Zepbound?
The slow climb itself is the first help: the labels set the starting dose and the four-week steps to lower the risk of stomach effects12. Day to day, the authors of the SURMOUNT analysis list simple food habits4, and the label adds fluids1:
- Split your day's food into smaller meals.
- Stop eating when you feel full, even with food left on the plate.
- Go easy on fatty food.
- Choose bland food on a queasy day.
- Drink fluids through the day, and more on any day with vomiting or diarrhoea, to keep from getting dehydrated.
If a dose stays hard to live with, the Zepbound label lets the prescriber choose a lower maintenance dose, the dose a person stays on1. That choice, like any dose change, is your prescriber's decision. The SURMOUNT authors also name a slower climb and short-term medicine for nausea or diarrhoea4.
Commonly reported: sulphur-tasting burps, food that suddenly sounds unappealing, a heavy full feeling after a normal-sized dinner, and a queasy day or two after a step-up that is milder by the third or fourth shot on that dose.
What other side effects does the label list?
- Hair loss: linked to the weight loss, and far more common in women: 7.1% of women and 0.5% of men on Zepbound. No one on Zepbound stopped because of it1.
- Injection site reactions: redness, itching or bruising where the shot went in; more common in people who made antibodies to tirzepatide1.
- Heart rate: an average rise of 1 to 3 beats a minute on Zepbound (none on placebo) and 2 to 4 on Mounjaro (1 on placebo)12.
- Low blood pressure: 1.6% on Zepbound against 0.1% on placebo, more often in people on blood-pressure medicine and alongside stomach upset or dehydration1.
- Low blood sugar: mainly when tirzepatide is taken with insulin or a sulfonylurea; in the Zepbound trial of people with diabetes, 4.2% had a reading under 54 mg/dL, against 1.3% on placebo1.
What are the serious side effects of tirzepatide?
The label lists them once, and in the weight trials most were rare. Pancreatitis, inflammation of the pancreas, was confirmed in 0.2% on Zepbound and 0.2% on placebo. Gallbladder inflammation was reported in 0.7% against 0.2%, and gallstones in 1.1% against 1%. Sudden kidney injury was reported in 0.5% against 0.2%; in reports after approval, most cases came with dehydration from vomiting or diarrhoea1.
The boxed warning is about thyroid C-cell tumours, seen in rats; whether tirzepatide causes them in people is not known, and the label rules it out for anyone with a personal or family history of medullary thyroid cancer or MEN 21. Serious allergic reactions have been reported after approval, and in the weight trials 0.1% had a severe one1. Because the stomach empties more slowly, the label asks that you tell your care team before any surgery or sedation. People with diabetic eye disease are watched for changes1.
When to get help Call your doctor the same day if you cannot keep fluids down, or have severe belly pain that does not go away, sometimes reaching the back; get emergency help for swelling of the face or throat or trouble breathing.
How do I keep track of side effects after each step-up?
A short record turns a hard week into something a prescriber can act on: the dose, the date of the step, what you felt and how strong. Note what you ate on the bad days too.
PepVault's side-effect log records each symptom with the compound, a severity from minimal to very severe, the date and a note, beside the dose log that keeps every weekly shot. Log it in PepVault
Sources
- ZEPBOUND (tirzepatide) prescribing information, DailyMed, August 2026 (sections 2.1, 5, 6.1, 12.2, 17 and the Medication Guide). dailymed.nlm.nih.gov
- MOUNJARO (tirzepatide) prescribing information, DailyMed, August 2026 (sections 2.1 and 6.1). dailymed.nlm.nih.gov
- Jastreboff AM et al.; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022. PubMed 35658024
- Rubino DM et al. Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials. Diabetes Obes Metab. 2025. PubMed 39789843
- Patel H et al. Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials. Diabetes Obes Metab. 2024. PubMed 37853960
- Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021. PubMed 34186022
- Frías JP et al.; SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021. PubMed 34170647
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.